DNA Damage in Pulmonary Arterial Hypertension and Veno-Occlusive Disease-FANCL as Dual Rescue?
作者信息
Pak Oleg, Weissmann Norbert, Sommer Natascha
机构信息
Institute for Lung Health (ILH) Universities of Giessen and Marburg Lung Center (UGMLC) Member of the German Center for Lung Research (DZL) Justus Liebig University Giessen Giessen, Germany.
出版信息
Am J Respir Crit Care Med. 2025 Aug;211(8):1337-1339. doi: 10.1164/rccm.202505-1114ED.
Abstract
摘要
相似文献
1
DNA Damage in Pulmonary Arterial Hypertension and Veno-Occlusive Disease-FANCL as Dual Rescue?
Am J Respir Crit Care Med. 2025 Aug;211(8):1337-1339. doi: 10.1164/rccm.202505-1114ED.
2
Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension.
Am J Respir Crit Care Med. 2025 Jun 6.
3
Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease.
Pediatr Radiol. 2019 May;49(5):575-585. doi: 10.1007/s00247-018-04331-y. Epub 2019 Jan 16.
4
Pulmonary veno-occlusive disease: a paradigm of diagnosis and therapeutic challenges in pulmonary hypertension.
Curr Opin Pulm Med. 2025 Sep 1;31(5):443-455. doi: 10.1097/MCP.0000000000001184. Epub 2025 Jun 5.
5
Pulmonary veno-occlusive disease.
Q J Med. 1975 Jan;44(173):133-59.
6
Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Bone Marrow Transplant. 2006 Apr;37(7):677-86. doi: 10.1038/sj.bmt.1705297.
7
Pulmonary veno-occlusive disease in a patient with recently diagnosed systemic sclerosis.
J Scleroderma Relat Disord. 2020 Jun;5(2):NP1-NP4. doi: 10.1177/2397198319852194. Epub 2019 Jun 7.
8
Endothelin receptor antagonists for pulmonary arterial hypertension.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD004434. doi: 10.1002/14651858.CD004434.pub3.
9
Pulmonary veno-occlusive disease: Two children with gradual disease progression.
Respir Med Case Rep. 2016 Dec 29;20:82-86. doi: 10.1016/j.rmcr.2016.12.007. eCollection 2017.
10
Pulmonary Arterial Hypertension After Busulfan Administration During Conditioning Regimen in Neuroblastoma: Key Role of Rescue Treatment.
JACC Case Rep. 2025 Jul 16;30(19):104050. doi: 10.1016/j.jaccas.2025.104050.
本文引用的文献
1
Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension.
Am J Respir Crit Care Med. 2025 Jun 6.
2
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
N Engl J Med. 2025 May 29;392(20):1987-2000. doi: 10.1056/NEJMoa2415160. Epub 2025 Mar 31.
3
Definition, classification and diagnosis of pulmonary hypertension.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01324-2024. Print 2024 Oct.
4
Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01095-2024. Print 2024 Oct.
5
Longitudinal clinical manifestations of Fanconi anemia: A systematized review.
Blood Rev. 2024 Nov;68:101225. doi: 10.1016/j.blre.2024.101225. Epub 2024 Aug 2.
6
Pulmonary veno-occlusive disease: illustrative cases and literature review.
Eur Respir Rev. 2024 Jan 17;33(171). doi: 10.1183/16000617.0156-2023. Print 2024 Jan 31.
7
Pulmonary Arterial Hypertension.
N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348.
8
Mechanism, specificity, and function of FANCD2-FANCI ubiquitination and deubiquitination.
FEBS J. 2022 Aug;289(16):4811-4829. doi: 10.1111/febs.16077. Epub 2021 Jun 29.
9
Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models.
Circulation. 2015 Sep 1;132(9):834-47. doi: 10.1161/CIRCULATIONAHA.115.014207. Epub 2015 Jun 30.
10
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.
Nat Genet. 2014 Jan;46(1):65-9. doi: 10.1038/ng.2844. Epub 2013 Dec 1.
Zotero 插件